Filing Details
- Accession Number:
- 0001209191-18-008215
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-07 18:07:16
- Reporting Period:
- 2018-02-05
- Accepted Time:
- 2018-02-07 18:07:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1504783 | Darin Lippoldt | 12780 El Camino Real San Diego CA 92130 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-05 | 1,979 | $18.15 | 15,136 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-05 | 1,979 | $83.11 | 13,157 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 758 | $83.13 | 14,574 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-06 | 787 | $82.48 | 16,062 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option | Disposition | 2018-02-05 | 1,979 | $18.15 | 1,979 | $18.15 |
| Common Stock | Stock Option | Acquisiton | 2018-02-05 | 26,050 | $0.00 | 26,050 | $81.49 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2018-02-05 | 4,600 | $0.00 | 4,600 | $0.00 |
| Common Stock | Restricted Stock Unit | Acquisiton | 2018-02-05 | 12,250 | $0.00 | 12,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 17,810 | 2024-11-03 | No | 4 | M | Direct | |
| 26,050 | 2028-02-05 | No | 4 | A | Direct | |
| 4,600 | No | 4 | A | Direct | ||
| 12,250 | 2021-03-15 | No | 4 | A | Direct |
Footnotes
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.20 to $84.70. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Sale of 758 shares of common stock issued upon vesting of 2,175 restricted stock units on February 5, 2018 to cover payroll and withholding taxes, with the balance of the shares (1,417) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth ina Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts theReporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $81.43 to $84.64. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Payment of tax liability by withholding 787 shares of Common Stock incident to the vesting of a security issued in accordance with Rule 16b-3, with the balance of the shares (1,488) maintained by the Reporting Person.
- Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018.
- Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 5, 2018 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter.
- Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 5, 2019, February 5, 2020, February 5, 2021, and February 5, 2022.
- A portion of this grant will vest upon FDA approval of opicapone within a specified time period, and portions of this grant will vest upon achievement of specified revenue milestones within a specified time period.
Billionaire Hedge Funds
